|Location||University of Queensland, UQ Graduate School|
|Eligibility||Australian residents only|
PhD in Clinical trial of nicotine vaporisers for smoking cessation $34,582 per year
Smoking is a leading cause of preventable death for priority populations with comorbidities (HIV, Hepatitis C and Opiate dependence) due to their high smoking prevalence, greater vulnerability to tobacco-related disease and low quit rates with current cessation therapies. This research will provide robust evidence on the effectiveness, safety and cost-effectiveness of offering nicotine maintenance in addition to standard cessation treatment to people living with comorbidities. This project responds to international calls improve quit rates among smokers with comorbidities and calls from government and public health organisations (e.g. WHO, RACP, NHMRC) for research on the safety and efficacy of nicotine vaporisers to be prioritised. This pragmatic, open-label randomised partial cross-over trial aims to evaluate if adding a nicotine maintenance intervention (a nicotine vaporiser) to standard quit support intervention improves quit rates for these populations and whether offering both interventions concurrently is more effective and cost-effective than offering the interventions sequentially.
This project is funded by a NHMRC project grant. A full scholarship or top-up scholarship is available for high quality applicants.
See our full disclaimer
Further Information / Application Enquiries
+61 7 33460503